42 research outputs found

    Non-AIDS defining cancers in the D:A:D Study-time trends and predictors of survival : a cohort study

    Get PDF
    BACKGROUND:Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these.METHODS:Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression.RESULTS:Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort.CONCLUSIONS:The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC

    Resolution of the arcs and linac BPM systems

    No full text
    The resolution obtained with two types of beam position monitors, the Linac model and the arc model, with their respective electronics are compared. Below 10/sup 10/ particles the Linac system yields a better resolution, but beyond 10/sup 10/ the Arcs system exhibits a resolution which is inversely proportional to the signal-to-noise ratio. (LEW

    Electronics for the control of the rf system

    No full text
    This note describes the operation of the major components used for controlling the phase and the field level of the PEP rf cavities. The block diagram of one rf station is decomposed into several control loops: each cavity has a tuners' servo loop which maintains the frequency constant and also keeps the field of each cell at the same level; the total gap voltage developed by a pair of cavities is obeying the command of the gap voltage controller; finally, the phase variation along the amplification chain and the klystron are compensated by a phase lock loop. The design criteria of each loop are set forth and the circuit implementation and test results are presented. The purpose of this report is to acquaint interested people with the design philosophy and to allow them to evaluate the capabilities of this system and its behavior during operation of the machine. 5 refs., 16 figs

    Beam excitation and damping with the transverse feedback system

    No full text
    The questions often come up, ''What is the strength if the beam excitation system. How much damping can the transverse feedback provide.'' The design is now advanced enough to answer these questions; also, laboratory tests of some components have been conducted and we know what can be expected of the hardware. This paper discusses these questions

    Activity of rifampicin against mollicutes, clostridia and L-forms

    No full text
    International audienc
    corecore